NGGT003
Phase 1Small molecule
NGGT003 is one of 21 small molecule programs targeting Hemophilia A. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RocheApproved
Rayos
RRoxane Laboratories
Approved
Cyklokapron
JJ Molner
Approved
Efanesoctocog Alfa
SanofiPhase 3
Advate
TakedaPhase 3
Marstacimab
PfizerPhase 3
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Rfviia
RochePhase 3
PF-06741086
PfizerPhase 3
SCT800
SSinocelltech Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NGGT003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details